The PIONEER Study: A multi‐center, randomized, double‐blind, placebo‐controlled phase 2 trial of the effects of T3D‐959 on safety, cognition, function and plasma biomarkers in mild to moderate Alzheimer’s disease subjects: Rationale and study design
medicine.medical_specialty Epidemiology business.industry Health Policy Clinical study design Cognition Disease Plasma biomarkers Placebo Double blind Psychiatry and Mental health Cellular and Molecular Neuroscience Physical medicine and rehabilitation Developmental Neuroscience medicine Center (algebra and category theory) Neurology (clinical) Geriatrics and Gerontology business